Emerging Lupus Nephritis Therapies: Addressing Unmet Needs through Innovation and Mechanistic Targeting
Lupus nephritis (LN), a severe manifestation of systemic lupus erythematosus (SLE), continues to challenge physicians and patients due to its complex pathology and resistance to conventional treatments. Characterized by inflammation of the kidneys, LN can lead to end-stage renal disease if not effectively managed. However, recent scientific breakthroughs and targeted innovations are reshaping the lupus nephritis therapy landscape, offering renewed hope to affected individuals. https://www.delveinsight.com/blog/emerging-lupus-nephritis-therapies?utm_source=blog&utm_medium=promotion&utm_campaign=gpr Innovation in the Lupus Nephritis Market The lupus nephritis market has witnessed considerable growth in recent years, driven by deeper understanding of the disease's immunopathology and the emergence of targeted biologics. Traditional immunosuppressants like corticosteroids and cyclophosphamide, while widely used, pose long-term safety concerns. To address these issues...